Product and trial design considerations on the path towards a vaccine to combat opioid overdose
Abstract Opioid overdose deaths are an evolving public health emergency in the United States. Recent advancements in drug conjugate vaccine design and adjuvantation technologies have re-ignited interest in the potential clinical utility of opioid vaccination. Here we present the concept of fentanyl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01083-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849724072868446208 |
|---|---|
| author | Asimenia Angelidou Jacob A. Koster Amy C. Sherman Caitlyn McLoughlin Pooja Lalwani Aisling Kelly Ahsan Saeed Kerry McEnaney Lindsey R. Baden Melissa Brogna Elissa R. Weitzman Sharon Levy David J. Dowling Ofer Levy |
| author_facet | Asimenia Angelidou Jacob A. Koster Amy C. Sherman Caitlyn McLoughlin Pooja Lalwani Aisling Kelly Ahsan Saeed Kerry McEnaney Lindsey R. Baden Melissa Brogna Elissa R. Weitzman Sharon Levy David J. Dowling Ofer Levy |
| author_sort | Asimenia Angelidou |
| collection | DOAJ |
| description | Abstract Opioid overdose deaths are an evolving public health emergency in the United States. Recent advancements in drug conjugate vaccine design and adjuvantation technologies have re-ignited interest in the potential clinical utility of opioid vaccination. Here we present the concept of fentanyl vaccination as a complementary strategy for opioid overdose prevention with a focus on vaccine safety, efficacy, and considerations for vaccine development and testing in early phase human clinical trials. |
| format | Article |
| id | doaj-art-6c37a7eabfbf4d7086d65507083da7a0 |
| institution | DOAJ |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-6c37a7eabfbf4d7086d65507083da7a02025-08-20T03:10:50ZengNature Portfolionpj Vaccines2059-01052025-02-011011810.1038/s41541-025-01083-3Product and trial design considerations on the path towards a vaccine to combat opioid overdoseAsimenia Angelidou0Jacob A. Koster1Amy C. Sherman2Caitlyn McLoughlin3Pooja Lalwani4Aisling Kelly5Ahsan Saeed6Kerry McEnaney7Lindsey R. Baden8Melissa Brogna9Elissa R. Weitzman10Sharon Levy11David J. Dowling12Ofer Levy13Precision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalDepartment of Medicine, Harvard Medical SchoolPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalDepartment of Medicine, Harvard Medical SchoolDivision of Addiction Medicine, Boston Children’s HospitalDepartment of Pediatrics, Harvard Medical SchoolDepartment of Pediatrics, Harvard Medical SchoolPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalPrecision Vaccines Program, Department of Pediatrics, Boston Children’s HospitalAbstract Opioid overdose deaths are an evolving public health emergency in the United States. Recent advancements in drug conjugate vaccine design and adjuvantation technologies have re-ignited interest in the potential clinical utility of opioid vaccination. Here we present the concept of fentanyl vaccination as a complementary strategy for opioid overdose prevention with a focus on vaccine safety, efficacy, and considerations for vaccine development and testing in early phase human clinical trials.https://doi.org/10.1038/s41541-025-01083-3 |
| spellingShingle | Asimenia Angelidou Jacob A. Koster Amy C. Sherman Caitlyn McLoughlin Pooja Lalwani Aisling Kelly Ahsan Saeed Kerry McEnaney Lindsey R. Baden Melissa Brogna Elissa R. Weitzman Sharon Levy David J. Dowling Ofer Levy Product and trial design considerations on the path towards a vaccine to combat opioid overdose npj Vaccines |
| title | Product and trial design considerations on the path towards a vaccine to combat opioid overdose |
| title_full | Product and trial design considerations on the path towards a vaccine to combat opioid overdose |
| title_fullStr | Product and trial design considerations on the path towards a vaccine to combat opioid overdose |
| title_full_unstemmed | Product and trial design considerations on the path towards a vaccine to combat opioid overdose |
| title_short | Product and trial design considerations on the path towards a vaccine to combat opioid overdose |
| title_sort | product and trial design considerations on the path towards a vaccine to combat opioid overdose |
| url | https://doi.org/10.1038/s41541-025-01083-3 |
| work_keys_str_mv | AT asimeniaangelidou productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT jacobakoster productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT amycsherman productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT caitlynmcloughlin productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT poojalalwani productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT aislingkelly productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT ahsansaeed productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT kerrymcenaney productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT lindseyrbaden productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT melissabrogna productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT elissarweitzman productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT sharonlevy productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT davidjdowling productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose AT oferlevy productandtrialdesignconsiderationsonthepathtowardsavaccinetocombatopioidoverdose |